GoldenGolden
Advanced Search
Hepion Pharmaceuticals

Hepion Pharmaceuticals

Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for the treatment of chronic liver disease.

Overview 

Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. The company designs targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH), hepatocelluluar carcinoma (HCC), and chronic hepatitis B, C, and D viruses (HBV, HCV, HDV). Hepion Pharmaceuticals was formerly called ContraVir Pharmaceuticals and spun-off from Synergy Pharmaceuticals through a SEC Form 10 filing in 2014. The company was founded on May 15, 2013 and is headquartered in Edison, NJ

AI-POWR

Hepion’s AI-POWR platform combines artificial intelligence, machine learning, and deep learning to decode disease, to develop targeted therapies, and to select patients that will respond to Hepion therapies. The platform provides an integrative, multi-variate, systems-biology bioinformatic, big-data analysis of pre-clinical and clinical data. AI-POWR utilizes publicly available databases to facilitate improved drug target selection, clinical study design, and a priori-responder analysis.

CRV431

CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. The drug candidate is a host-targeting antiviral that reduces important viral proteins, such as those involved in host cell entry and viral replication. Specifically, CRV431 reduces liver fibrosis and hepatocellular carcinoma tumor burden and is a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. As of May 2020, the drug candidate completed Phase 1 trials and advanced to Phase 2 trials for NASH fibrosis.

COVID-19 Applications

On July 7, 2020, Hepion Pharmaceuticals announced that its clinical phase, anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease. Firstly, CRV431 demonstrated strong anti-inflammatory actions in a non-viral, acute lung injury model and on some measures outperformed dexamethasone, a recommended treatment for COVID-19. Secondly, cell culture experiments demonstrated CRV431 antiviral activity towards SARS-CoV-2, the virus responsible for COVID-19 disease. On December 22, 2020 the FDA approved Hepion Pharmaceuticals’ investigational new drug (IND) application for CRV431 as a treatment to COVID-19.

Timeline

February 18, 2021
Hepion Pharmaceuticals, Inc. announces closing of public offering.

Hepion Pharmaceuticals, Inc., announces the closing of its previously announced public offering of 44,200,000 shares of its common stock at a public offering price of $2.00 per share.

February 16, 2021
Hepion Pharmaceuticals, Inc. announces pricing of public offering.

Hepion Pharmaceuticals, Inc., announces the pricing of its underwritten public offering of 44,200,000 shares of its common stock at a public offering price of $2.00 per share.

February 12, 2021
Hepion Pharmaceuticals, Inc. announces proposed public offering of common stock.

Hepion Pharmaceuticals, Inc. announces that it intends to offer to sell shares of its common stock in an underwritten public offering, and that all of the shares of common stock will be sold by the company itself.

December 22, 2020
The FDA approves Hepion Pharmaceuticals’ investigational new drug (IND) application for CRV431 as a treatment to COVID-19. 
November 30, 2020
Hepion Pharmaceuticals announces public offering of common stock.
November 24, 2020
Hepion Pharmaceuticals prices public offering.

Hepion Pharmaceuticals, Inc. announces the pricing of an underwritten public offering of 20,000,000 shares of its common stock. Each share of common stock is being sold to the public at a price per share of $1.50. 

July 7, 2020
Hepion Pharmaceuticals announces that CRV431 as a possible treatment to COVID-19.

Hepion Pharmaceuticals announces that its clinical phase, anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease.

May 2020
Hepion’s clinical phase, lead oral drug candidate, CRV431 completes Phase 1 trials and advances to Phase 2.

Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease, CRV 431, completes Phase 1 trials and advances to Phase 2 trials for NASH fibrosis.

February 14, 2014
Hepion Pharmaceuticals raises a $3,200,000 venture round.
2014
Hepion Pharmaceuticals spins-off from Synergy Pharmaceuticals through a SEC Form 10 filing.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Amidst a global pandemic, two biotech companies offer innovative solutions - BioTuesdays

Abby Hardy

Web

March 31, 2020

CRV431 Overview - Hepion Pharmaceuticals

Web

Hepion Pharmaceuticals - Funding, Financials, Valuation & Investors

Web

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19

BioSpace

Web

December 22, 2020

Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial

BioSpace

Web

August 5, 2020

Documentaries, videos and podcasts

Title
Date
Link

074 - Hepion Tackles NASH in P2 with Cyclophilin Inhibitor | Interview with HEPA CEO Robert Foster

October 11, 2020

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Annalee Armstrong
July 13, 2021
FierceBiotech
Hepion Pharmaceuticals' liver disease drug is heading for a phase 2b trial after data from a midstage trail confirmed safety and tolerability while also collecting a bit of data that suggest efficacy. CRV431 is being tested in patients with nonalcoholic steatohepatitis, which is when a buildup of fat in the liver causes scarring and damage.
BioSpace
May 6, 2021
BioSpace
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it has completed recruitment for its Phase 2a 'AMBITION' clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled.

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.